Matrixyl: anti-wrinkle cosmetic peptide (Palmitoyl Pentapeptide-4, Pal-KTTKS)
A skin-care peptide that tells collagen-making skin cells to produce more collagen, helping reduce the look of wrinkles; sold in cosmetics, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
What this is
Matrixyl is the trade name for palmitoyl pentapeptide-4 (Pal-KTTKS), a lipopeptide consisting of palmitic acid conjugated to the five-amino-acid sequence Lys-Thr-Thr-Lys-Ser. The KTTKS sequence is a fragment of the procollagen type I C-terminal propeptide, making it a matrikine — a matrix-derived signaling fragment that prompts skin fibroblasts to produce more extracellular matrix. The palmitoyl conjugation is essential: without the C16 fatty-acid chain, the bare hydrophilic pentapeptide stalls at the lipid-rich stratum corneum and cannot reach viable epidermis (Choi and colleagues 2014; Mortazavi and colleagues 2022). The stored sequence here — KTTKS — is the bare backbone only; the palmitoyl chain is absent from that notation but is the part of the molecule responsible for skin delivery.
Matrixyl is classified and regulated as a cosmetic ingredient in all major markets. It is not a drug, not approved for any therapeutic indication, and injectable use has no clinical basis.
History
Matrixyl was developed by Sederma in the late 1990s. The design was rooted in matrikine biology: fragments of extracellular matrix proteins, released naturally during tissue remodeling, act as signaling molecules that instruct fibroblasts to rebuild more matrix. The KTTKS pentapeptide was selected as a fragment of the procollagen type I C-terminal propeptide, conjugated to palmitic acid to allow delivery through the outer skin barrier. A clinical study in photoaged human facial skin (Robinson and colleagues 2005) provided early published evidence of wrinkle-depth reduction with topical Pal-KTTKS.
A later formulation, Matrixyl 3000, combined palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR), extending the anti-aging pitch from collagen stimulation alone to also include anti-inflammatory signaling via IL-6 modulation. Further variants (Matrixyl Synthe'6, Matrixyl Morphomics) have continued the commercial line.
What it does
Matrixyl signals skin fibroblasts to produce more structural proteins — collagen types I, III, and IV, fibronectin, and elastin — by mimicking the appearance of degraded matrix. Fibroblasts sense the KTTKS fragment as a breakdown product and respond by upregulating matrix production. The intended result with topical use is gradual improvement in skin firmness and reduction in wrinkle depth over weeks of application. The palmitoyl modification allows the otherwise hydrophilic peptide to partition into the outer skin layer; studies of Pal-KTTKS penetration show that only a small fraction of the applied dose reaches viable epidermis in typical cosmetic vehicles, making formulation vehicle an important variable (Choi and colleagues 2014; Mortazavi and colleagues 2022).
Evidence
- Human: A 12-week double-blind, placebo-controlled split-face trial in 93 Caucasian women aged 35–55 with photoaged skin found improvement in several skin appearance measures with topical Pal-KTTKS vs. moisturizer control (Robinson and colleagues, International Journal of Cosmetic Science 2005). Published efficacy data is largely manufacturer-associated or licensee-associated; independent clinical replication at fully powered controlled endpoints is a key limitation of the current evidence base.
- Animal / preclinical: Collagen and extracellular matrix protein stimulation demonstrated in fibroblast cultures and wound-healing models.
- In vitro: Fibroblast collagen gene upregulation (types I, III, IV), fibronectin, and elastin. IL-6 modulation reported for palmitoyl tetrapeptide-7 (the Matrixyl 3000 component). Skin-permeation studies show Pal-KTTKS penetrates the stratum corneum more effectively than bare KTTKS but delivery to viable epidermis remains limited in typical cosmetic formulations (Choi and colleagues 2014).
Known effects
- Wrinkle-depth reduction (topical) — Human clinical evidence; modest and manufacturer-associated
- Skin-firmness improvement (topical) — Human clinical evidence; manufacturer-associated trials
- Fibroblast collagen stimulation — In vitro well-demonstrated; clinical magnitude inferred from wrinkle endpoints, not direct biopsy collagen measurement
- Anti-inflammatory signaling (Matrixyl 3000 only) — Mechanistic / in vitro (IL-6 reduction by palmitoyl tetrapeptide-7); clinical contribution not separately quantified
Safety signals
Matrixyl and its formulation variants are consistently reported as well-tolerated in published cosmetic studies. Rare mild skin sensitivity is the most commonly noted finding. Contact dermatitis is uncommon and is generally attributed to vehicle components (preservatives, fragrances, emulsifiers) rather than the peptide itself. No systemic adverse events have been identified in published literature, consistent with low systemic absorption expected from topical application.
Cosmetic Matrixyl preparations are not sterile injectable products. Published literature explicitly states that injectable use has no clinical basis — these formulations are topical actives only.
No dedicated pregnancy or pediatric safety data exist. Most published trials run 8–16 weeks; multi-year safety data are absent from the available literature.
Regulatory status
- US (FDA): Regulated as a cosmetic ingredient under FDA cosmetic law; over-the-counter sale in finished cosmetic formulations is permitted without prescription. Palmitoyl pentapeptide-4 is not approved as a drug for any indication.
- EU: Permitted cosmetic ingredient; palmitoyl-peptide cosmetic ingredients assessed as safe at typical formulation levels by relevant bodies.
- UK, Canada, Australia, Japan and other major markets: Permitted cosmetic ingredient; no major jurisdiction treats palmitoyl-peptide cosmetics as prescription or regulated substances.
- WADA: Not listed on the Prohibited List; negligible systemic exposure from topical use; not a realistic doping concern.
Mechanism
The KTTKS sequence is a matrikine derived from the procollagen type I C-terminal propeptide. Fibroblasts sense this fragment as a degradation product of extracellular matrix and respond by activating TGF-β-family signaling, upregulating gene expression for collagen types I, III, and IV, fibronectin, and elastin.
The palmitoyl conjugation is the key formulation engineering step. Palmitic acid dramatically improves partition of the otherwise hydrophilic pentapeptide into the lipid-rich stratum corneum. Even so, in vitro permeation experiments confirm that only a small fraction of applied Pal-KTTKS reaches viable epidermis across typical cosmetic vehicles; formulation vehicle affects delivered dose more than nominal peptide concentration above approximately 3–5% (Choi and colleagues 2014; Mortazavi and colleagues 2022).
In the Matrixyl 3000 variant, palmitoyl tetrapeptide-7 (Pal-GQPR) adds a second signaling component: reduction of IL-6 production in skin cells, targeting chronic low-grade dermal inflammation that degrades extracellular matrix. Palmitoyl tripeptide-1 (Pal-GHK), the other Matrixyl 3000 component, overlaps chemically with the GHK tripeptide sequence relevant to copper peptide biology.
TGF-β-family pathway activation in fibroblasts is well-characterized at the in vitro level. The clinical magnitude of this pathway's contribution to measured wrinkle-depth changes in human trials is inferred from wrinkle and firmness endpoints rather than confirmed by direct tissue biopsy collagen quantification.
Open questions
- Independent clinical replication: Most published in vivo efficacy data for Matrixyl variants is manufacturer-associated or licensee-associated. Non-industry-funded trials at clinically relevant concentrations and durations are a critical evidence gap.
- Head-to-head comparison with established actives: Whether topical Matrixyl produces meaningful additional benefit alongside a retinoid, or comparable benefit as a standalone, has not been established by head-to-head trials versus tretinoin, retinol, or vitamin C.
- Human skin delivery quantification: Quantification of active Pal-KTTKS delivery to viable epidermis and papillary dermis across commercial formulations is limited. Real-world effective dose at the fibroblast varies substantially by vehicle and is not well characterized.
- Matrixyl 3000 vs. original Pal-KTTKS: The clinical advantage of the 3000 formulation over the original has not been demonstrated by head-to-head in vivo trial data at the level of robust wrinkle-depth differences, despite in vitro rationale.
- Long-term use data: Most trials run 8–16 weeks. Whether chronic use over years affects skin-aging trajectory differently from shorter windows has not been studied.
- Responder characterization: Clinical response is variable. The biological basis for inter-individual variability (skin thickness, baseline collagen status, concurrent actives, formulation vehicle) is not well mapped.
Related peptides
- Argireline — Acetyl hexapeptide-3 (Ac-EEMQRR-NH₂); a neuromodulatory cosmetic peptide that targets SNARE complex assembly rather than collagen signaling; often co-formulated with Matrixyl.
- Syn-Coll — Palmitoyl tripeptide-5 (Pal-KVK); a TGF-β signal peptide from a different sequence lineage with a similar topical collagen-stimulation premise.
- GHK-Cu — Copper tripeptide; the GHK sequence overlaps with the palmitoyl tripeptide-1 (Pal-GHK) component of Matrixyl 3000; shares the fibroblast collagen-signaling biology (card not yet linked).
- SNAP-8 — Eight-residue extension of Argireline targeting SNARE inhibition; frequently co-formulated with Matrixyl-family peptides in anti-aging products (card not yet linked).
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the fatty acid tail do more than just help the peptide enter skin: could it actually grip the cell receptor itself?
If true, chemists could design better anti-aging ingredients by tuning the lipid part, not just the peptide. This could lead to stronger, gentler, or longer-lasting cosmetic actives for the skincare industry.
What if you joined two KTTKS peptides into one molecule: would skin cells respond more strongly?
If true, manufacturers could make a more powerful anti-aging ingredient using the same simple chemistry, without inventing entirely new molecules. This could lead to better wrinkle creams and possibly stronger wound-healing products.
Is there a specific receptor on skin cells that recognizes the KTTKS fragment and tells fibroblasts to make more collagen?
If researchers find this receptor, they could design much more precise anti-aging treatments. It would also help explain why Matrixyl works for some people but not others, and whether it could be adapted for medical skin repair.
If you swapped one of the lysine amino acids in Matrixyl, would it still tell fibroblasts to make collagen, or would it stop working?
If true, chemists could tweak those lysines to make Matrixyl stronger, longer-lasting, or less likely to cause irritation. It would turn guesswork into precise peptide design.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.7737100124359131 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep10769,
sequence = {KTTKS},
target = {cosmeceutical},
author = {peptidemodel},
year = {2026},
status = {computed}
}